The PRRX1-COL6A3 axis, and modulators thereof yet to be discovered, may represent promising treatment targets for mitigating obesity-related pathogenesis, including insulin resistance and cancer. Here, PRRX1 is linked to obesity due to melanocortin 4 receptor deficiency.